NCT00452140View on ClinicalTrials.gov

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2007

Study Completion Date

February 28, 2009

Conditions
Metastatic Breast CancerAdvanced Breast Cancer
Interventions
BIOLOGICAL

ertumaxomab

10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.

Trial Locations (5)

Unknown

Study Site

Study Site

Study Sites

Study Site

Barcelona

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
lead

Neovii Biotech

INDUSTRY

NCT00452140 - Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment | Biotech Hunter | Biotech Hunter